^
Association details:
| Biomarker: | VHL mutation |
|---|---|
| Cancer: | Clear Cell Renal Cell Carcinoma |
| Drug: | pazopanib (Multi-tyrosine kinase inhibitor) |
| Direction: | Resistant |
Evidence:
Source:
Title:
The role of aberrant VHL/HIF pathway elements in predicting clinical outcome to pazopanib therapy in patients with metastatic clear-cell renal cell carcinoma
Excerpt:
When examined in relation to clinical outcome, VHL mutation and/or methylation status did not correlate with either ORR (ORR 37.5% vs. 41.4% in patients with VHL [n=70] vs. without VHL gene inactivation [n=8], respectively; Table 1) or PFS (median PFS was 13.8 months vs. 17.4 months in patients with vs. without VHL gene inactivation, respectively...
DOI:
10.1158/1078-0432.CCR-13-0491
